Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an antiparasitic drug boost radiation against childhood brain tumors?

NCT ID NCT06624371

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding the drug atovaquone to standard radiation therapy is safe and tolerable for children with certain malignant brain tumors, including high-grade glioma, diffuse midline glioma, and medulloblastoma. The study includes two groups: children newly diagnosed with these tumors, and those whose tumors have returned or progressed. The goal is to see if this combination can be given without unacceptable side effects, and to gather initial information on how well it might work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atovaquone (an antiparasitic drug) combined with standard radiation therapy
What this could lead to
If safe and effective, this combination could offer a new way to improve outcomes for children with aggressive brain tumors, potentially slowing tumor growth or improving response to radiation.
What could go wrong
This is an early-phase trial with a small number of participants, so the main goal is safety, not proof of benefit. The drug may not improve outcomes, and there are risks of side effects and radiation-related brain injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma diffuse midline glioma, H3 K27M-mutant glioma malignant glioma medulloblastoma pediatric high-grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE INTRINSIC PONTINE GLIOMA DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT HIGH GRADE GLIOMA MEDULLOBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Arthur M Blank Hospital

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Email: •••••@•••••

  • Children's Healthcare of Atlanta: Scottish Rite

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.